FDA panel backs speedy approval of Intercept's liver drug

(Reuters) - An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously backed the accelerated approval of Intercept Pharmaceuticals Inc's drug to treat a rare liver condition.